Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Document:EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022: Difference between revisions

From GxPlex

Jump to: navigation, search
← Older edit
m 1 revision imported
Remove static References table, superseded by live #ask in Template:DocumentData (GxPlexBot)
 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
<noinclude>{{#set:
{{DocumentData
|DocReference=EU  GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS
DURING THE COVID-19 (CORONAVIRUS) PANDEMIC  v5
10-Feb-2022
|DocValidityArea=EU
|DocScopes=G
|DocName=GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS
DURING THE COVID-19 (CORONAVIRUS) PANDEMIC
|DocVersion=v5
10-Feb-2022
|DocStatus=Current
|DocType=Official recommendation
|DocLanguage=EN
|DocDescription=GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC
|DocRestricted=No
|DocSubmittedBy=Florian Adragna
|DocContributors=
}}</noinclude>
 
{{DocumentBox
|reference=EU  GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS
|reference=EU  GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS
DURING THE COVID-19 (CORONAVIRUS) PANDEMIC  v5
DURING THE COVID-19 (CORONAVIRUS) PANDEMIC  v5
Line 37: Line 18:
|contributors=
|contributors=
}}
}}
<noinclude>
== References ==
{| class="wikitable" style="width:100%;"
! Reference !! Scope !! Document part !! Language !! Preview
|-
| [[Reference:EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022 11 d)]] || G || 11
d) || EN || d) Remote source data verification […] Remote SDV may be considered for trials: - involving COVID-19 treatment or prevention; - investigating serious or life-threatening conditions; - where the ...
|-
| [[Reference:EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022 Annex 1]] || G || Annex 1 || EN || Annex 1: Protection of trial participants’ rights during remote source data verification […] - A documented risk assessment should be performed […] - Site staff and monitors should be trained on the ...
|}
</noinclude>

Latest revision as of 14:15, 16 July 2026


Document information
Reference EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS

DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022

Validity area EU
Scope(s) G
Document name GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS

DURING THE COVID-19 (CORONAVIRUS) PANDEMIC

Version / Revision v5

10-Feb-2022

Status Current
Document type Official recommendation
Language(s) EN
Description GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC
Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors

References

 ScopeDocument partLanguagePreview
EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022 11 d)G11 d)ENd) Remote source data verification

[…] Remote SDV may be considered for trials: - involving COVID-19 treatment or prevention;

- investigating serious …
EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022 Annex 1GAnnex 1ENAnnex 1: Protection of trial participants’ rights during remote source data verification

[…] - A documented risk assessment should be performed […]

- …
Retrieved from "https://gxplex.org/index.php?title=Document:EU_GUIDANCE_ON_THE_MANAGEMENT_OF_CLINICAL_TRIALS_DURING_THE_COVID-19_(CORONAVIRUS)_PANDEMIC_v5_10-Feb-2022&oldid=20336"